This alert card contains important safety information that you need to be aware of before you are given CIMZIA and during treatment with CIMZIA.

Please refer to the Patient Information Leaflet that comes with your CIMZIA prefilled syringes for further safety information.
Keep this card with you at all times and show this card to any doctor you see for medical treatment.

**Infections**

CIMZIA® increases the risk of getting infections. Infections may progress more rapidly and be more severe. This includes tuberculosis (TB).

Prior to treatment with CIMZIA®:

- You must not be treated with CIMZIA® if you have a serious infection.
- You should be screened for hepatitis B infection. If you are a carrier of hepatitis B infection you should be closely monitored for the signs and symptoms of active hepatitis B infection. CIMZIA® should be discontinued in patients who develop active hepatitis B infection.
- You should be screened for TB. It is very important that you tell your doctor if you have ever had TB, or if you have been in close contact with someone who has had TB.

Please record the dates of the last screening for TB below:

- Tuberculin test/IGRA:
- Chest x-ray:

During CIMZIA® treatment:

- If you develop symptoms suggestive of an infection, such as fever, persistent cough, weight loss, or tiredness, seek medical attention immediately.

**Heart Failure**

Prior to treatment with CIMZIA®

- Physicians should exercise caution in patients with heart failure. You must not use CIMZIA® if you have moderate to severe heart failure.

During CIMZIA® treatment:

- If you develop symptoms that can potentially be related to heart failure (e.g., shortness of breath or swelling of the feet) tell your doctor.

**Allergic Reactions**

If you experience symptoms that could be due to allergic reactions such as chest tightness, wheezing, dizziness, swelling or rash, stop using CIMZIA® and contact your doctor immediately. Some of these reactions could occur after the first administration of CIMZIA®.
Patients receiving vaccinations:
- Please be aware that live or live-attenuated vaccines should not be administered concurrently with CIMZIA®.

Patients requiring surgery:
- If you require surgery on CIMZIA® you should be closely monitored for infection and appropriate action taken as necessary.

Malignancies
- The use of anti-TNF therapy may increase the risk of cancer. If you develop unexplained weight loss or fatigue, tell your doctor. However, alone these symptoms are not necessarily indicative of cancer.

Reporting of side effects:
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the patient information leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or the IMB at www.imb.ie. Please also report to Medical Information at UCB Pharma Ltd on 01753 534655

Assay Interaction
Please inform your doctors if you are receiving anti-coagulant therapy or if you have a clotting test performed. Interference with certain tests of blood clotting (coagulation assays) has been detected in patients treated with CIMZIA®. CIMZIA® may erroneously cause these tests to indicate prolonged clotting time when none exists. There is no evidence that CIMZIA® therapy has an effect on blood clotting (in vivo coagulation).

Any prescriber providing medical treatment to this patient should refer to the CIMZIA® product information.

Dates of CIMZIA® Treatment
1st injection: ________________________________
Following injections: ____________________________

Patient’s Name: _______________________________
GP’s Name and Phone: ___________________________
Specialist’s Name and Phone: ___________________
- See the Patient Information Leaflet for more information.
- Please make sure you also have a list of all your other medicines with you at any visit to a health care professional.

Please keep this card with you for 5 months after your last CIMZIA® dose, since side effects may occur a long time after your last dose.

Patients receiving vaccinations:
- Please be aware that live or live-attenuated vaccines should not be administered concurrently with CIMZIA®.

Patients requiring surgery:
- If you require surgery on CIMZIA® you should be closely monitored for infection and appropriate action taken as necessary.

Malignancies
- The use of anti-TNF therapy may increase the risk of cancer. If you develop unexplained weight loss or fatigue, tell your doctor. However, alone these symptoms are not necessarily indicative of cancer.

Reporting of side effects:
- If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the patient information leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or the IMB at www.imb.ie. Please also report to Medical Information at UCB Pharma Ltd on 01753 534655

Assay Interaction
Please inform your doctors if you are receiving anti-coagulant therapy or if you have a clotting test performed. Interference with certain tests of blood clotting (coagulation assays) has been detected in patients treated with CIMZIA®. CIMZIA® may erroneously cause these tests to indicate prolonged clotting time when none exists. There is no evidence that CIMZIA® therapy has an effect on blood clotting (in vivo coagulation).

Any prescriber providing medical treatment to this patient should refer to the CIMZIA® product information.

Dates of CIMZIA® Treatment
1st injection: ________________________________
Following injections: ____________________________

Patient’s Name: _______________________________
GP’s Name and Phone: ___________________________
Specialist’s Name and Phone: ___________________
- See the Patient Information Leaflet for more information.
- Please make sure you also have a list of all your other medicines with you at any visit to a health care professional.

Please keep this card with you for 5 months after your last CIMZIA® dose, since side effects may occur a long time after your last dose.